Mirabegron (ER) & Solifenacin Succinate Tablets – SOLZIX M 5/50

Mirabegron (ER) & Solifenacin Succinate Tablets – A Comprehensive Solution for a Calmer, More Comfortable Day.

SOLZIX M 5/50: The Dual combination of Mirabegron 50mg + Solifenacin 5mg targets overactive bladder (OAB) symptoms and offers improved symptom control, reduced incontinence episodes, and better quality of life. Mirabegron is a selective beta-3 adrenergic agonist that targets beta-3 receptors in the bladder, which, when activated, leads to relaxation of the detrusor muscle during the storage phase, thereby increasing bladder capacity and reducing the frequency and urgency of urination. Solifenacin is an antimuscarinic agent that selectively antagonizes muscarinic receptors, particularly M3 receptors, in the bladder. This inhibition prevents acetylcholine from binding to these receptors, reducing involuntary bladder contractions and increasing bladder storage capacity by blocking muscarinic receptors.

Recommended By Specialists:
Nephrologists – It is preferred to treat the disease associated with some cases of urinary urgency/frequency related to kidney or bladder disorders.
Urologists –It is preferredpreferred to treat the disease associated with overactive bladder, especially when monotherapy is ineffective.

Key benefits of Mirabegron (ER) & Solifenacin Succinate Tablets – SOLZIX M 5/50
FDA Approval : These Dual combination approved with the FDA for underscoring the efficacy & safety with OAB symptoms support.
Well Tolerated Profile : To studies indicate the combination therapy of generally well tolerated with the adverse of associated with morbidity and impairement .
Enhanced Efficacy: To demonstrate the significant combination that is used to treat considerable inconveniences such as urinary incontinence, frequency, and urgency, compared to monotherapy

INDICATIONS:
Overactive bladder
Increase bladder inconvenience
Urinary Incontinence (due to OAB)